Dermapharm Holding SE

DMP

Equity

ISIN DE000A2GS5D8 / Valor 40166352

Xetra (2024-11-19)

EUR 35.05+1.74%

Dermapharm Holding SE
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Dermapharm Holding SE is a pharmaceutical company that operates through its subsidiary HÜBNER Naturarzneimittel GmbH, also known as MEDOPHARM Arzneimittel GmbH & Co. KG. Founded in 1932 in Munich, the company specializes in natural preparations for pharmacies, particularly silica products. Dermapharm is a leading manufacturer of branded pharmaceuticals, medical devices, and food supplements, with a focus on steroids, dermatics, and painkillers. The company's integrated business model includes in-house development, production, and distribution of healthcare products in Germany, Europe, and the United States. With a strong emphasis on innovation and rapid growth, Dermapharm is dedicated to providing high-quality pharmaceuticals and healthcare products to its customers.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Growth

In the first quarter of 2023, Dermapharm Holding SE reported a significant increase in revenue, reaching EUR 319.1 million. This represents a 37.8% growth compared to the previous year's first quarter revenue of EUR 231.6 million.

EBITDA Increase

Dermapharm Holding SE's adjusted EBITDA for Q1 2023 rose by 40.9%, amounting to EUR 105.8 million. This is a substantial increase from the EUR 75.1 million reported in the same period of the previous year.

Annual Revenue

For the full year 2023, Dermapharm Holding SE achieved a total revenue of EUR 1,135.4 million. This marks a 10.8% increase from the EUR 1,024.8 million recorded in the previous year.

Profit Decline

Despite the revenue growth, Dermapharm Holding SE's profit for the period in 2023 was EUR 60.5 million, which is a decrease from the EUR 132.6 million profit reported in 2022.

Dividend Payout

Dermapharm Holding SE declared a dividend of EUR 0.88 per share for the financial year 2023. This is a reduction from the EUR 1.05 per share dividend paid out in the previous year.

Summarized from source with an LLMView Source

Key figures

-11.4%1Y

-56.2%3Y

-1.27%5Y

Performance

26.4%1Y

32.6%3Y

33.3%5Y

Volatility